Anna Koget, DO
Hematology & Oncology · Pittsburgh, PANPI 1750607404
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,929 of the $9,261 with a category attached, or 74.8%. E.r. Squibb & Sons, L.L.C. accounts for 75.1% of it on its own, with 11 other manufacturers making up the rest. 2025 is the largest year on record at $5,351, more than ten times the $185 reported in 2019.
Across 24 payments — averaging $385.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$7K
- Bristol Myers Squibb$2K
- Seagen Inc.$94
- Jazz Pharmaceuticals Inc.$72
- Adaptive Biotechnologies Corporation$50
- Incyte Corporation$26
- plus $110 from 6 others
Across 59 payments — averaging $2191.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$44K
- Incyte Corporation$37K
- E.r. Squibb & Sons, L.L.C.$35K
- Sumitomo Pharma America, Inc.$14K
What the payments were for
- Consulting fees$6,92975%
- Travel & lodging$1,43315%
- Food & beverage$8059%
- Education$941%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 4 | $6,958 |
| Bristol Myers Squibb | 10 | $1,951 |
| Seagen Inc. | 1 | $94 |
| Jazz Pharmaceuticals Inc. | 1 | $72 |
| Adaptive Biotechnologies Corporation | 1 | $50 |
| Incyte Corporation | 1 | $26 |
| Blueprint Medicines Corporation | 1 | $20 |
| Gilead | 1 | $19 |
| Sanofi | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Pfizer | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
How this compares
$9,261 in reported general payments places this provider in the 75th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SprycelDasatinib | 45 | $733,779 |
| InrebicFedratinib Dihydrochloride | 13 | $340,154 |
| JakafiRuxolitinib Phosphate | 17 | $278,628 |
| InqoviDecitabine/Cedazuridine | 15 | $116,354 |
| VenclextaVenetoclax | 61 | $106,589 |
| Imatinib Mesylate | 21 | $76,980 |
| Tretinoin | 17 | $34,851 |
| EliquisApixaban | 27 | $15,353 |
| Voriconazole | 39 | $12,770 |
| Acyclovir | 225 | $2,438 |
| Fluconazole | 26 | $2,315 |
| Hydroxyurea | 55 | $860 |
| Potassium Chloride | 26 | $820 |
| MethotrexateMethotrexate Sodium | 15 | $551 |
| Ondansetron OdtOndansetron | 11 | $436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sprycel | $6,958 | $733,77945 claims |
| Bristol Myers SquibbInrebic | $1,951 | $340,15413 claims |
| Incyte CorporationJakafi | $26 | $278,62817 claims |
| PfizerEliquis | $16 | $15,35327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 682 hematology & oncology providers in Pennsylvania.
Other hematology & oncology in Pittsburgh
- Salman FazalPittsburgh$2.3M
- Cyrus KhanPittsburgh$1.9M
- Alexander BarsoukPittsburgh$674K
- Hashem YounesPittsburgh$435K
- Taofeek OwonikokoPittsburgh$346K
- Jason LukePittsburgh$300K
- Ahmad TarhiniPittsburgh$216K
- Diwakar DavarPittsburgh$104K
- Jing Zhou HouPittsburgh$78K
- Vikram GorantlaPittsburgh$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.